v3.26.1
Segment Disclosures (Tables)
3 Months Ended
Mar. 31, 2026
Segment Disclosures  
Schedule of significant expense categories regularly reviewed by the CODM

  ​ ​ ​

Three Months Ended March 31, 

2026

2025

(in thousands)

 

  ​

 

  ​

Partnership revenue

$

$

732

Product revenue

 

110

 

136

Expenses:

Cost of product revenues

 

32

 

44

Non-clinical development costs

 

4,050

 

4,465

Clinical development costs

 

3,574

 

2,942

Personnel and consulting costs

 

8,788

 

6,664

Stock-based compensation

 

2,851

 

2,965

Depreciation and amortization expense

 

90

 

83

Other segment expenses(1)

 

595

 

2,626

Interest expense (income), net

 

821

 

(166)

Net loss

$

(20,691)

$

(18,755)

(1)Other segment expenses primarily include the gain on the sale of strategic investments as well as general and administrative costs not presented in other line items.